Skip to main content
polskiPL
European Commission logo print header

Study of immunogenicity of DNA HIV-1 env, gag and pol plasmid vaccines boosted with MVA in Tanzania; HIV vaccine immunogenicity study

Cel

HIV-l vaccines are urgently needed especially in developing nations. HIV vaccine study sites are needed in developing nations for more rapid development and deployment of vaccines. DNA plasmid vaccines are promising candidates - Their potency needs to be improved. The programme will explore various modes of increasing the immunogenicity of priming with plasmid DNA; intradermal injections, with GM-CSF as adjuvant, intramucosal injections and boosting with a Modified Vaccinia Ankara vector, MVA. Vaccines produced from subtypes appropriate for Tanzania will be used. A study site will be established in Dar es Salaam- The prerequisites for approval will be addressed on all levels, paving the way to future trials - Immunogenicity studies will continue in Dar es Salaam, with a focus on mucosal immunity and durability of the immune response.

Dziedzina nauki

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

KAROLINSKA INSTITUTE
Wkład UE
Brak danych
Adres
Ringwaegen, 52
11883 STOCKHOLM
Szwecja

Zobacz na mapie
Koszt całkowity
Brak danych

Uczestnicy (4)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 13 Czerwca 2006

Moja broszura

Permalink: https://cordis.europa.eu/project/id/ICA4-CT-2002-10036/pl

European Union, 2024